NASDAQ •
Healthcare •
Drug Manufacturers - Specialty & Generic •
Quote as of 06/26/2026 16:00
Company Profile
IndustryDrug Manufacturers - Specialty & Generic
SectorHealthcare
ExchangeNASDAQ
Market Capitalization1,747.02 mln
Float102 mln
Earnings Date08/03/2026
EPS
2.65
Solid
P / E
3.84
Deeply undervalued
Piotroski F-Score
4
/ 9
Borderline
Beneish M-Score
-1.24
Manipulation likely
1-Year Forecast
22.83
Transformational upside
Relative Strength
23
/ 100
Significantly lagging
Business Description
HUTCHMED (China) Limited is a Hong Kong-based biopharmaceutical company founded in 2000 that researches and brings to market treatments for cancer and immune system diseases across global markets. The company has built a broad portfolio of medicines targeting a wide range of conditions, including colorectal, lung, gastric, and kidney cancers, as well as blood disorders such as leukemia and lymphoma. Several of its drugs are already approved and in use, while others are progressing through clinical trials. HUTCHMED works alongside major pharmaceutical partners including AstraZeneca, Lilly, and Takeda to advance its pipeline.
